Identification of treatment efficacy-related host factors in chronic hepatitis C by proteinchip serum analysis

Molecular Medicine

Volumn 17, Issue 1-2, 2011, Pages 70-78

  Fujita, Naoki ^a   Nakanishi, Mamoru ^b   Mukai, Jun ^b   Naito, Yuuji ^c   Ichida, Takafumi ^d   Kaito, Masahiko ^e   Yoshikawa, Toshikazu ^c   Takei, Yoshiyuki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Biomarker Science Co Ltd   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^e Mie Gastroenterological Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; FERRITIN; HEMOPEXIN; IRON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRANSFERRIN;

ADULT; ARTICLE; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; FIBROGENESIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION PROFILING; HEMOPEXIN; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PROTEIN ARRAY ANALYSIS; RIBAVIRIN; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78651472974     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00124     Document Type: Article

References (43)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. (2003) Viral hepatitis C. Lancet. 362:2095-2100.
2. Seeff LB. (2002) Natural history of chronic hepatitis C. Hepatology. 36 Suppl 1:S35-S46.
3. Manns MP, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:958-965.
4. Fried MW, et al. (2002) Pegintereron alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
5. Berg T, et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 130:1086-1097.
6. Paweletz CP, et al. (2000) Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev. Res. 49:34-42.
7. Issaq HJ, Veenstra TD, Conrads TP, Helshow D. (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292:587-592.
8. Wiesner A. (2004) Detection of tumor markers with ProteinChip technology. Curr. Pharm. Biotechnol. 5:45-67.
9. Xiao Z, et al. (2001) Quantification of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 15:6029-6033.
10. Petricoin EF, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:572-577.
11. Paradis V, et al. (2005) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology. 41:40-47.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1513-1520.
13. Shevchenko A, Wilm M, Vorm O, Mann M. (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68:850-858.
14. Fujita N, et al. (2007) Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol. Med. 13:97-104.
15. Smith A, Morgan WT. (1979) Haem transport to the liver by haemopexin: receptor-mediated uptake with recycling of the protein. Biochem. J. 182:47-54.
16. Tolosano E, Altruda F. (2002) Hemopexin: structure, function, and regulation. DNA Cell Biol. 21:297-306.
17. National Institutes of Health. (2002) National Institutes of Health. Consensus Development Statement: management of hepatitis. Hepatology. 36 Suppl 1:S3-S20.
18. Neumann AU, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 282:103-106.
19. Enomoto N, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:77-81.
20. Akuta N, et al. (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol. 46:403-410.
21. Gao B, Hong F, Radaeva S. (2004) Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 39:880-890.
22. Fujita N, et al. (2007) Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J. Gastroenterol. Hepatol. 22:1886-1893.
23. Tanaka Y, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109.
24. Suppiah V, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41:1100-1104.
25. Popescu CI, Dubuisson J. (2009) Role of lipid metabolism in hepatitis C virus assembly and entry. Biol. Cell. 28;102:63-74.
26. Voisset C, et al. (2006) High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J. Gen. Virol. 87:2577-2581.
27. Voisset C, et al. (2005) High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280:7793-7799.
28. Dreux M, et al. (2007) The exchangeable apolipo - protein ApoC-I promotes membrane fusion of hepatitis C virus. J. Biol. Chem. 282:32357-32369.
29. Pumeechockchai W, et al. (2002) Hepatitis C virus particles of different density in the blood of chronically infected immunocompetent and immunodeficient patients: implications for virus clearance by antibody. J. Med. Virol. 68:335-342.
30. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. (1992) Measurements of iron status in patients with chronic hepatitis. Gastroenterolgy. 102:2108-2113.
31. Haque S, Chandra B, Gerber MA, Lok ASF. (1996) Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum. Pathol. 27:1277-1281.
32. Van Thiel DH, et al. (1994) Response to interferon α therapy is influenced by the iron content of the liver. J. Hepatol. 20:410-415.
33. Olynyk JK, et al. (1995) Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology. 108:1104-1109.
34. Fontana RJ, et al. (2000) Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 31:730-736.
35. Fargion S, et al. (2002) Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of Italian multicenter randomized study. Am. J. Gastroenterol. 97:1204-1210.
36. Guyader D, et al. (1999) A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am. J. Gastroenterol. 94:1696-1698.
37. Di Bisceglie AM, et al. (2000) Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology. 32:135-138.
38. Gutteridge JM, Smith A. (1988) Antioxidant protection by haemopexin of haem-stimulated lipid peroxidation. Biochem. J. 256:861-865.
39. Tolosano E, et al. (1999) Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice. Blood. 94:3906-3914.
40. Tolosano E, et al. (2002) Enhanced splenomegaly and severe liver inflammation in hepatoglobin/hemopexin double-null mice after acute hemolysis. Blood. 100:4201-4208.
41. Sumida Y, et al. (2000) Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J. Hepatol. 33:616-622.
42. Horiike S, et al. (2005) Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J. Hepatol. 43:403-410.
43. Fujita N, et al. (2007) Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C. Free Radic. Biol. Med. 42:353-362.